titoli, abstracts, parole chiave >>>
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

Fattovich, Giovanna and Giustina, Giuliano and Sanchez Tapias, José and Quero, Carlos and Mas, Anna and Olivotto, Pia Grazia and Solinas, Antonio and Almasio, Piero Luigi and Hadziyannis, Stephanos and Degos, Françoise and De Moura, Miguel Carneiro and Krogsgaard, Kim and Pantalena, Maurizio and Realdi, Giuseppe (1998) Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. The American Journal of Gastroenterology, Vol. 93 (6), p. 896-900. eISSN 1572-0241. Article.

Full text not available from this repository.

Alternative URLs:


OBJECTIVE: The aim of this study was to evaluate the incidence, prognostic factors and clinical significance of delayed clearance of serum HBsAg in compensated cirrhosis B.
METHODS: This was a retrospective cohort study of 309 consecutive white patients with biopsy-proved compensated cirrhosis type B.

RESULTS: During a mean follow-up of 68 months, HBsAg loss occurred in 32 patients, including 16 (8%) of 196 untreated patients (mean annual incidence 0.8%), 8 (10%) of 82 interferon (IFN) alpha-treated patients and eight patients who had been treated with other antivirals or steroids. The 5-yr probability of HBsAg loss was 4% and 16% for untreated and IFN-treated patients, respectively (p = 0.0001). Cox's regression analysis identified hepatitis B e antigen-positivity at entry as the sole independent prognostic factor for HBsAg loss. Of the 32 patients who lost HBsAg, one (3%) subsequently developed hepatocellular carcinoma (HCC) and died, whereas, among the patients who remained HBsAg-positive, 11% developed HCC and 20% had died. The probability of HCC appearance was lower (p = 0.0137) and survival was longer (p = 0.0006) in patients who cleared HBsAg compared with patients with HBsAg persistence.

CONCLUSION: The incidence of HBsAg loss is about 0.8% in cirrhosis type B. Prognostic factors for clearance of HBsAg are initial HBeAg positivity and therapy with alpha interferon. Patients with cirrhosis type B, who lose HBsAg, have a low risk for liver cancer or liver-related death.

Item Type:Article
ID Code:6870
Uncontrolled Keywords:Serum HBsAg, cirrhosis B, disease prognosis
Subjects:Area 06 - Scienze mediche > MED/12 Gastroenterologia
Divisions:001 Università di Sassari > 03 Istituti > Clinica medica generale e terapia medica
001 Università di Sassari > 01 Dipartimenti > Scienze biomediche
Publisher:Nature Publishing Group
Deposited On:14 Dec 2011 11:23

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page